TY - JOUR T1 - Factors associated with progression to critical illness in 28 days among COVID-19 patients: results from a tertiary care hospital in Istanbul, Turkey JF - medRxiv DO - 10.1101/2020.10.09.20209775 SP - 2020.10.09.20209775 AU - Uluhan Sili AU - Pinar Ay AU - Ahmet Topuzoglu AU - Huseyin Bilgin AU - Elif Tukenmez Tigen AU - Buket Erturk Sengel AU - Dilek Yagci Caglayik AU - Baran Balcan AU - Derya Kocakaya AU - Sehnaz Olgun Yildizeli AU - Fethi Gul AU - Beliz Bilgili AU - Rabia Can Sarinoglu AU - Aysegul Karahasan Yagci AU - Lutfiye Mulazimoglu Durmusoglu AU - Emel Eryuksel AU - Zekaver Odabasi AU - Haner Direskeneli AU - Sait Karakurt AU - Ismail Cinel AU - Volkan Korten Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/10/11/2020.10.09.20209775.abstract N2 - Background Coronavirus disease 2019 (COVID-19) quickly spread worldwide to become a pandemic. This study aimed to define the predictors of critical illness development within 28 days postadmission.Methods We conducted a prospective cohort study including 477 PCR-positive COVID-19 patients admitted to a tertiary care hospital in Istanbul from March 12 to May 12, 2020. The development of critical illness, e.g., invasive mechanical ventilation and/or death, was followed for a period of 28 days postadmission. Demographic characteristics, number of comorbidities, illness severity at admission defined by the WHO scale, vital signs, laboratory findings and period of admission to the hospital were independent variables. Cox proportional hazards analysis was performed, and the C-index was calculated.Results The median (IQR) age of the cohort was 55.0 (44.0-67.0) years, and 50.1% were male. The most common presenting symptoms were cough, dyspnea and fatigue. Overall, 65.2% of the patients had at least one comorbidity. Hydroxychloroquine was given to 99.2% of the patients. Critical illness developed in 45 (9.4%; 95% CI: 7.0%-12.4%) patients. In the multivariable analysis, age (HR: 1.05, p<0.001), number of comorbidities (HR: 1.33, p=0.02), procalcitonin ≥0.25 µg/L (HR: 2.12, p=0.03) and LDH ≥350 U/L (HR: 2.04, p=0.03) were independently associated with critical illness development. The WHO scale on admission was the strongest predictor of critical illness (HR: 4.15, p<0.001). Prognosis improved within the study period (p<0.05). The C-index of the model was 0.92.Conclusions Age, comorbidity number, WHO scale, LDH and procalcitonin were independently associated with critical illness development. Mortality from COVID-19 seems to be decreasing as the pandemic advances.summary We analyzed 477 confirmed COVID-19 patients for the development of critical illness, e.g., invasive mechanical ventilation and/or death within 28 days postadmission. Age, comorbidity number, WHO scale, LDH and procalcitonin were independently associated with critical illness development.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo special funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the ethics board of Marmara University, School of Medicine (09.2020.572). The requirement for written informed consent was waived by the board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available on request from the corresponding authors [US and VK]. The data are not publicly available due to them containing information that could compromise research participant privacy. ER -